Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab-based combinations versus pemetrexed/platinum after failure of first-line EGFR TKI in EGFR-mutant T790M-negative NSCLC
2017-002672-38Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab, ipilimumab, pemetrexed, cisplatin and carboplatin in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival. Started Sep 2017; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-002672-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002672-38.